320 related articles for article (PubMed ID: 27714708)
1. Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer.
Corominas-Faja B; Vellon L; Cuyàs E; Buxó M; Martin-Castillo B; Serra D; García J; Lupu R; Menendez JA
Histol Histopathol; 2017 Jul; 32(7):687-698. PubMed ID: 27714708
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
3. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.
Baumann J; Wong J; Sun Y; Conklin DS
BMC Cancer; 2016 Jul; 16():551. PubMed ID: 27464732
[TBL] [Abstract][Full Text] [Related]
4. Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer.
Menendez JA; Mehmi I; Papadimitropoulou A; Vander Steen T; Cuyàs E; Verdura S; Espinoza I; Vellon L; Atlas E; Lupu R
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081219
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.
Vazquez-Martin A; Colomer R; Brunet J; Lupu R; Menendez JA
Cell Prolif; 2008 Feb; 41(1):59-85. PubMed ID: 18211286
[TBL] [Abstract][Full Text] [Related]
6. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.
Jin Q; Yuan LX; Boulbes D; Baek JM; Wang YN; Gomez-Cabello D; Hawke DH; Yeung SC; Lee MH; Hortobagyi GN; Hung MC; Esteva FJ
Breast Cancer Res; 2010; 12(6):R96. PubMed ID: 21080941
[TBL] [Abstract][Full Text] [Related]
7. Fatty acid synthase inhibition by amentoflavone suppresses HER2/neu (erbB2) oncogene in SKBR3 human breast cancer cells.
Lee JS; Sul JY; Park JB; Lee MS; Cha EY; Song IS; Kim JR; Chang ES
Phytother Res; 2013 May; 27(5):713-20. PubMed ID: 22767439
[TBL] [Abstract][Full Text] [Related]
8. The mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cells.
Yan C; Wei H; Minjuan Z; Yan X; Jingyue Y; Wenchao L; Sheng H
PLoS One; 2014; 9(5):e97697. PubMed ID: 24866893
[TBL] [Abstract][Full Text] [Related]
9. Effects of anti-proliferative lichen metabolite, protolichesterinic acid on fatty acid synthase, cell signalling and drug response in breast cancer cells.
Bessadóttir M; Skúladóttir EÁ; Gowan S; Eccles S; Ögmundsdóttir S; Ogmundsdóttir HM
Phytomedicine; 2014 Oct; 21(12):1717-24. PubMed ID: 25442282
[TBL] [Abstract][Full Text] [Related]
10. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
Blancafort A; Giró-Perafita A; Oliveras G; Palomeras S; Turrado C; Campuzano Ò; Carrión-Salip D; Massaguer A; Brugada R; Palafox M; Gómez-Miragaya J; González-Suárez E; Puig T
PLoS One; 2015; 10(6):e0131241. PubMed ID: 26107737
[TBL] [Abstract][Full Text] [Related]
11. Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75.
Puig T; Vázquez-Martín A; Relat J; Pétriz J; Menéndez JA; Porta R; Casals G; Marrero PF; Haro D; Brunet J; Colomer R
Breast Cancer Res Treat; 2008 Jun; 109(3):471-9. PubMed ID: 17902053
[TBL] [Abstract][Full Text] [Related]
12. Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib.
Li CF; Fang FM; Chen YY; Liu TT; Chan TC; Yu SC; Chen LT; Huang HY
Clin Cancer Res; 2017 Aug; 23(16):4908-4918. PubMed ID: 28442505
[No Abstract] [Full Text] [Related]
13. Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells.
Yoon S; Lee MY; Park SW; Moon JS; Koh YK; Ahn YH; Park BW; Kim KS
J Biol Chem; 2007 Sep; 282(36):26122-31. PubMed ID: 17631500
[TBL] [Abstract][Full Text] [Related]
14. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
Tomek K; Wagner R; Varga F; Singer CF; Karlic H; Grunt TW
Mol Cancer Res; 2011 Dec; 9(12):1767-79. PubMed ID: 21970855
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.
Menendez JA; Mehmi I; Verma VA; Teng PK; Lupu R
Mol Carcinog; 2004 Nov; 41(3):164-78. PubMed ID: 15390078
[TBL] [Abstract][Full Text] [Related]
16. Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients.
Vazquez-Martin A; Fernandez-Real JM; Oliveras-Ferraros C; Navarrete JM; Martin-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2009 Dec; 35(6):1369-76. PubMed ID: 19885560
[TBL] [Abstract][Full Text] [Related]
17. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer.
Rahman MT; Nakayama K; Ishikawa M; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Iida K; Miyazaki K
Oncology; 2013; 84(3):166-73. PubMed ID: 23306391
[TBL] [Abstract][Full Text] [Related]
18. Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer.
Oliveras G; Blancafort A; Urruticoechea A; Campuzano O; Gómez-Cabello D; Brugada R; López-Rodríguez ML; Colomer R; Puig T
Ann N Y Acad Sci; 2010 Oct; 1210():86-92. PubMed ID: 20973802
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis.
Goswami S; Sharma-Walia N
Oncotarget; 2016 Sep; 7(37):58953-58974. PubMed ID: 27270654
[TBL] [Abstract][Full Text] [Related]
20. Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells.
Veigel D; Wagner R; Stübiger G; Wuczkowski M; Filipits M; Horvat R; Benhamú B; López-Rodríguez ML; Leisser A; Valent P; Grusch M; Hegardt FG; García J; Serra D; Auersperg N; Colomer R; Grunt TW
Int J Cancer; 2015 May; 136(9):2078-90. PubMed ID: 25302649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]